Charles Schwab
ZYME icon

Charles Schwab’s Zymeworks ZYME Stock Holding History

Charles Schwab’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98M Sell
152,416
-32,708
-18% -$831K ﹤0.01% 2562
2026
Q1 		$4.64M Sell
185,124
-35,785
-16% -$847K ﹤0.01% 2433
2025
Q4 		$5.82M Buy
220,909
+27,549
+14% +$601K ﹤0.01% 2377
2025
Q3 		$3.3M Buy
193,360
+69,156
+56% +$990K ﹤0.01% 2600
2025
Q2 		$1.56M Sell
124,204
-9,435
-7% -$112K ﹤0.01% 2749
2025
Q1 		$1.59M Buy
133,639
+2,333
+2% +$31.8K ﹤0.01% 2686
2024
Q4 		$1.92M Sell
131,306
-1,492
-1% -$20.9K ﹤0.01% 2692
2024
Q3 		$1.67M Buy
132,798
+650
+0.5% +$7.08K ﹤0.01% 2758
2024
Q2 		$1.12M Buy
132,148
+6,657
+5% +$59.3K ﹤0.01% 2890
2024
Q1 		$1.32M Hold
125,491
– – ﹤0.01% 2712
2023
Q4 		$1.3M Buy
125,491
+3,625
+3% +$28.9K ﹤0.01% 2754
2023
Q3 		$773K Sell
121,866
-162
-0.1% -$1.2K ﹤0.01% 2882
2023
Q2 		$1.05M Buy
+122,028
New +$1.09M ﹤0.01% 2755

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Charles Schwab's ZYME Position: Q2 2026 in Review

Charles Schwab reduced its Zymeworks (ZYME) stake by 18% in Q2 2026, selling an estimated $831K and leaving 152,416 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2562.

Charles Schwab first reported a position in ZYME in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.82M in Q4 2025. 202 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

  • Charles Schwab held 152,416 shares of Zymeworks worth $3.98M as of Q2 2026.
  • Charles Schwab sold 32,708 Zymeworks shares in Q2 2026, an estimated $831K.
  • Zymeworks made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2562 holding.
  • Charles Schwab first reported a position in Zymeworks in Q2 2023 and has held it in 13 quarters since.
  • Charles Schwab's Zymeworks position peaked at $5.82M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.